Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Third Autologous Salvage Transplant at Late Myeloma Relapse Is Associated with Favourable Overall Survival and Contributes to Improvement of Exhausted Bone Marrow Function

Susanne Strifler, MD, Inken Hilgendorf, MD, Martina Kleber, MD, Christoph Röllig, MD, Lars-Olof Mügge, MD, Maria-Veronica Teleanu, MD, Brigitte Kragl, MD, Hermann Einsele, MD, Stefan Knop, MD

Blood (2014) 124 (21): 3988.

https://doi.org/10.1182/blood.V124.21.3988.3988

Published: 2014

Journal Articles

First Results of the Interdisciplinary Comprehensive Cancer Center Freiburg (CCCF) Tumor Board (TB) Multiple Myeloma (MM) Assessing TB-Questions, TB-Advice Adherence, TB-Satisfaction of Patients, Participants and Referring Physicians, Inclusion of Difficult-to-Treat-MM Pts in Clinical Trials (CT) and Patient Outcome

Ricarda Selder, Masa Pandurevic, Mandy-Deborah Möller, Johannes Waldschmidt, MD, Milena Pantic, Georg W. Herget, Karl Henne, Annette May, Martina Kleber, MD, Josefina Udi, MD, Gabriele Ihorst, Rainer Bredenkamp, Werner Vach, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 2635.

https://doi.org/10.1182/blood.V124.21.2635.2635

Published: 2014

Journal Articles

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Anne-Saskia Domm, Stefanie Hieke, Gabriele Ihorst, Milena Pantic, Bernd Koch, Martina Kleber, MD, Johannes Waldschmidt, MD, Martin Schumacher, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 733.

https://doi.org/10.1182/blood.V124.21.733.733

Published: 2014

Journal Articles

Comparison of 4 Previously Established, but Highly Different Comorbidity Scores (Kaplan Feinstein Index [KF], Charlson-Comorbidity Index [CCI], Satariano Index [SI], Hematopoietic cell transplantation-specific comorbidity index [HCT-CI]) Identifies the KF and HCT-CI as Most Relevant, but Use of An Easily Applied 3-Risk-Factor (KLeber) -Score Suggests to Even More Effectively Predict Progression-Free- and Overall-Survival Differences in Multiple Myeloma (MM) Patients (pts).

Meike Terhorst, Martina Kleber, MD, Gabriele Ihorst, David De Pasquale, Monika Engelhardt

Blood (2009) 114 (22): 1797.

https://doi.org/10.1182/blood.V114.22.1797.1797

Published: 2009

Journal Articles

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Martina Kleber, MD, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt

Blood (2009) 114 (22): 4945.

https://doi.org/10.1182/blood.V114.22.4945.4945

Published: 2009

Journal Articles

Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines

Werner Neubauer, Martina Kleber, MD, Alf Zerweck, MD, Veronique Thierry, MD, Alexandra Goebel, PhD, Beate Lubrich, PhD, Hartmut Bertz, MD, Monika Engelhardt, MD

Blood (2008) 112 (11): 1313.

https://doi.org/10.1182/blood.V112.11.1313.1313

Published: 2008

Journal Articles

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Martina Kleber, MD, Gabriele Ihorst, PhD, Christian Jakob, MD, Peter Liebisch, MD, Bernd Koch, PhD, Monika Engelhardt, MD

Blood (2007) 110 (11): 4830.

https://doi.org/10.1182/blood.V110.11.4830.4830

Published: 2007

Journal Articles

Prognostic Impact of Clinico-Pathological Parameters on the Outcome of Multiple Myeloma Patients: A Single-Center Analysis on 143 Consecutive Patients Treated with Standard Versus Intensive Chemotherapy.

Truc Ngo, MD, Martina Kleber, MD, Barbara Deschler, MD, Gabriele Ihorst, Monika Engelhardt, MD

Blood (2006) 108 (11): 5436.

https://doi.org/10.1182/blood.V108.11.5436.5436

Published: 2006

Journal Articles

Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Martina Kleber, MD, Truc Ngo, MD, Gabriele Ihorst, Bernd Koch, Monika Engelhardt, MD

Blood (2006) 108 (11): 5497.

https://doi.org/10.1182/blood.V108.11.5497.5497

Published: 2006

Journal Articles

Peripheral Blood, Cord Blood and Bone Marrow Cells Sorted into SP+, CD34+ and SP− Cells Are Distinct in Their ABCG2 and MDR1 Expression Levels, Which Are Most Increased in SP+ Cells and Substantially Decline after In Vitro Culture and Terminal Cell Differentiation.

Martina Kleber, MD, Rebecca Storz, Y. Guo, MD, Dagmar Wider, Gabriele Ihorst, Monika Engelhardt, MD

Blood (2006) 108 (11): 4154.

https://doi.org/10.1182/blood.V108.11.4154.4154

Published: 2006

Journal Articles

Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.

Martina Kleber, MD, Kris Bauchmüller, Gabriele Ihorst, Bernd Koch, Monika Engelhardt, MD

Blood (2005) 106 (11): 2250.

https://doi.org/10.1182/blood.V106.11.2250.2250

Published: 2005

NARROW

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Third Autologous Salvage Transplant at Late Myeloma Relapse Is Associated with Favourable Overall Survival and Contributes to Improvement of Exhausted Bone Marrow Function

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Prognostic Impact of Clinico-Pathological Parameters on the Outcome of Multiple Myeloma Patients: A Single-Center Analysis on 143 Consecutive Patients Treated with Standard Versus Intensive Chemotherapy.

Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Peripheral Blood, Cord Blood and Bone Marrow Cells Sorted into SP+, CD34+ and SP− Cells Are Distinct in Their ABCG2 and MDR1 Expression Levels, Which Are Most Increased in SP+ Cells and Substantially Decline after In Vitro Culture and Terminal Cell Differentiation.

Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only